Case number 1:21-cv-01782
Novo Nordisk Inc. et al v. Teva Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 26, 2023 | 112 | NOTICE OF SERVICE of (1) Reply Expert Report of Christopher A. Vellturo, Ph.D.; (2) Reply Expert Report of Andreas Pfützner, M.D., Ph.D.; (3) Reply Expert Report of Peter M. Tessier, Ph.D. regarding Secondary Considerations; (4) Reply Expert Report of Peter M. Tessier, Ph.D. regarding Infringement; and (5) Reply Expert Report of Kimberly Cameron, P.hD. - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/26/2023) (5) |
| Jun 26, 2023 | 113 | NOTICE OF SERVICE of (1) Reply Expert Report of Dr. Robert J. Orr Regarding the Invalidity of U.S. Patent No. 8,144,833; and (2) Reply Expert Report of Karl R. Leinsing, M.S.M.E., P.E. U.S. Patent Nos. 9,265,893 & 9,101,718 filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 06/26/2023) (2) |
| Jun 6, 2023 | 110 | STIPULATION TO EXTEND TIME to submit Reply Expert Reports to June 23, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/06/2023) (3) |
| Jun 6, 2023 | 111 | SO ORDERED, re 110 STIPULATION TO EXTEND TIME to submit Reply Expert Reports to June 23, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/6/2023. (kmd) (Entered: 06/06/2023) (3) |
| May 30, 2023 | 109 | NOTICE OF SERVICE of 1) Rebuttal Expert Report of Karl R. Leinsing, M.S.M.E., P.E. U.S. Patent Nos. 9,265,893 and 9,101,718 2) Expert Report of Dr. Robert J. Orr, Ph.D. on the Non-Infringement and Obviousness of U.S. Patent No. 8,114,833 3) Rebuttal Expert Report of Ivan T. Hofmann filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 05/30/2023) (2) |
| May 26, 2023 | 108 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Peter M. Tessier, Ph.D. Regarding Validity of U.S. Patent No. 8,114,833; (2) Rebuttal Expert Report of Kimberly Cameron, Ph.D. Regarding Validity of U.S. Patent No. 9,265,893 and U.S. Patent No. 9,101,718; and (3) Rebuttal Expert Report of Virender Kumar Sarin Regarding Validity of U.S. Patent No. 8,114,833 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/26/2023) (5) |
| May 1, 2023 | 107 | NOTICE OF SERVICE of 1) Opening Expert Report of Karl R. Leinsing M.S.M.E., P.E. Invalidity of U.S. Patent Nos. 9,265,893 and 9,101,718 2) Opening Expert Report of Dr. Robert J. Orr on the Invalidity of U.S. Patent No. 8,114,833 filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 05/01/2023) (2) |
| Apr 28, 2023 | 106 | NOTICE OF SERVICE of (1) Opening Expert Report of Kimberly Cameron, Ph.D. and Appendices A-C; (2) Opening Expert Report of Andreas Pfützner, M.D., Ph.D. Regarding Nonobviousness and Exhibits A-B; (3) Opening Expert Report of Peter M. Tessier, Ph.D. Regarding Patent Infringement of U.S. Patent No. 8,114,833 and Exhibits A-B; (4) Opening Expert Report of Peter M. Tessier, Ph.D. Regarding Secondary Considerations and Exhibits A-B; and (5) Opening Expert Report of Christopher A. Vellturo, Ph.D. and Exhibits 1-10 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/28/2023) (5) |
| Apr 17, 2023 | 105 | NOTICE OF SERVICE of Defendants' Second Amended Non-Infringement Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 04/17/2023) (2) |
| Apr 14, 2023 | 104 | NOTICE OF SERVICE of Novo Nordisk's Amended Responses to Defendants' Third Amended Preliminary Invalidity Contentions Regarding U.S. Patent Nos. 8,114,833; 9,101,718; and 9,265,893 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/14/2023) (4) |
| Apr 7, 2023 | 103 | REDACTED VERSION of 98 Stipulation - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 04/07/2023) (9) |
| Apr 5, 2023 | 102 | NOTICE OF SERVICE of Defendants' Third Amended Preliminary Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 04/05/2023) (2) |
| Apr 4, 2023 | 101 | NOTICE OF SERVICE of Plaintiffs' First Amended Infringement Contentions Regarding the '833 and '893 Patents and Second Amended Infringement Contentions Regarding the '718 Patent - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/04/2023) (4) |
| Apr 3, 2023 | 100 | [SEALED] SO ORDERED, re 98 Joint Stipulation and Order Regarding Authenticity and Business Record Status of Certain Records, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 4/3/2023.This order has been emailed to local counsel. (kmd) (Entered: 04/03/2023) (0) |
| Mar 31, 2023 | 98 | [SEALED] STIPULATION and [Proposed] Order Regarding Authenticity and Business Record Status of Certain Records - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/31/2023) (0) |
| Mar 31, 2023 | 99 | REDACTED VERSION of 90 MOTION for Issuance of Hague Convention Letter of Request to Obtain Evidence in Switzerland - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit 1, # 2 Attachments A-D)(Murray, Travis) (Entered: 03/31/2023) (Main Document) (10) |
| Mar 31, 2023 | 99 | REDACTED VERSION of 90 MOTION for Issuance of Hague Convention Letter of Request to Obtain Evidence in Switzerland - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit 1, # 2 Attachments A-D)(Murray, Travis) (Entered: 03/31/2023) (Exhibit 1) (15) |
| Mar 31, 2023 | 99 | REDACTED VERSION of 90 MOTION for Issuance of Hague Convention Letter of Request to Obtain Evidence in Switzerland - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit 1, # 2 Attachments A-D)(Murray, Travis) (Entered: 03/31/2023) (Attachments A-D) (30) |
| Mar 30, 2023 | 97 | MOTION for Pro Hac Vice Appearance of Attorney Eliana Applebaum - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 03/30/2023) (4) |
| Mar 28, 2023 | 95 | [SEALED] ORDER granting 90 MOTION for Issuance of Hague Convention Letter of Request to Obtain Evidence in Switzerland . Signed by Judge Colm F. Connolly on 3/28/2023.This order has been emailed to local counsel. (nmf) (Entered: 03/28/2023) (0) |
| Mar 28, 2023 | 96 | [SEALED] ORDER - Hague Convention Letter of Request to Obtain Evidence in Switzerland. Signed by Judge Colm F. Connolly on 3/28/2023.This order has been emailed to local counsel. (nmf) (Entered: 03/28/2023) (0) |
| Mar 27, 2023 | 93 | SO ORDERED, re 92 Joint STIPULATION TO EXTEND TIME for previously noticed depositions to take place after the close of the fact discovery period to mutually agreeable dates, filed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. Signed by Judge Colm F. Connolly on 3/27/2023. (kmd) (Entered: 03/27/2023) (2) |
| Mar 27, 2023 | 94 | NOTICE OF SERVICE of 1. Defendants' Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 73-83) 2. Defendants' Objections and Responses to Plaintiffs' First Set of Requests for Admission to Defendants (Nos. 1-25) 3. Defendants' Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 15-25) 4. Defendants' Objections and Responses to Plaintiffs' Second Set of Requests for Admission to Defendants (Nos. 26-97) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 03/27/2023) (2) |
| Mar 24, 2023 | 90 | [SEALED] MOTION for Issuance of Hague Convention Letter of Request to Obtain Evidence in Switzerland - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit 1 - Document Letter of Request, # 2 Attachments A-D)(Murray, Travis) (Entered: 03/24/2023) (0) |
| Mar 24, 2023 | 91 | NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses and Objections to Defendants' First Set of Interrogatory Requests (Nos. 1-5, 7-12) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/24/2023) (3) |
| Mar 24, 2023 | 92 | Joint STIPULATION TO EXTEND TIME for previously noticed depositions to take place after the close of the fact discovery period to mutually agreeable dates - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 03/24/2023) (2) |
| Mar 21, 2023 | 89 | NOTICE OF SERVICE of Plaintiffs' Final Election of Asserted Claims Pursuant to Paragraph 23 of the Scheduling Order - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/21/2023) (4) |
| Mar 17, 2023 | 88 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Requests for Admission (Nos. 1-5) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/17/2023) (3) |
| Mar 13, 2023 | 87 | NOTICE OF SERVICE of Defendants' First Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-14) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 03/13/2023) (2) |
| Mar 10, 2023 | 86 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Interrogatory Requests (Nos. 13-17) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/10/2023) (4) |
| Mar 9, 2023 | 85 | NOTICE OF SERVICE of Defendants' 30(b)(1) Notice of Deposition of Pater Buus filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 03/09/2023) (2) |
| Mar 8, 2023 | 82 | NOTICE to Take Deposition of Lina Lahoz on March 20, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/08/2023) (4) |
| Mar 8, 2023 | 83 | NOTICE OF SERVICE of Defendants' First Amended Non-Infringement Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 03/08/2023) (2) |
| Mar 8, 2023 | 84 | NOTICE OF SERVICE of Plaintiffs' First Amended Infringement Contentions Regarding the '718 Patent - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/08/2023) (4) |
| Mar 3, 2023 | 80 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/03/2023) (4) |
| Mar 3, 2023 | 81 | NOTICE OF SERVICE of (1) Plaintiffs' Second Amended Disclosures Under Paragraph 3 of the District of Delaware Default Standard and (2) Plaintiffs' Second Amended Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure - filed by Novo Nordisk A/S.(Murray, Travis) (Entered: 03/03/2023) (4) |
| Feb 23, 2023 | 79 | NOTICE OF SERVICE of (1) Plaintiffs' Second Set of Interrogatories (Nos. 15-25), (2) Plaintiffs' First Set of Requests for Admission to Defendants (Nos. 1-25), (3) Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 73-83), and (4) Plaintiffs' Second Set of Requests for Admission to Defendants (Nos. 26-97) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/23/2023) (5) |
| Feb 8, 2023 | 74 | NOTICE to Take Deposition of Brandon Wood on March 13, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/08/2023) (4) |
| Feb 8, 2023 | 75 | NOTICE to Take Deposition of Chris Smith on March 15, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/08/2023) (4) |
| Feb 8, 2023 | 76 | NOTICE to Take Deposition of Ross Vaughan on March 17, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/08/2023) (4) |
| Feb 8, 2023 | 77 | NOTICE to Take Deposition of David Barton on March 21, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/08/2023) (4) |
| Feb 8, 2023 | 78 | NOTICE to Take Deposition of Tijana Ljubicic on March 23, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/08/2023) (4) |
| Feb 7, 2023 | 73 | REDACTED VERSION of 69 Notice to Take Deposition by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 02/07/2023) (8) |
| Feb 6, 2023 | 71 | NOTICE OF SERVICE of 1. Defendants Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.'s Second Amended Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery 2.Defendants' Notice of Deposition of Plaintiffs Novo Nordisk, Inc. and Novo Nordisk A/S filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 72 | SO ORDERED, re 70 STIPULATION - Claim Construction Order. Signed by Judge Colm F. Connolly on 2/6/2023. (nmf) (Entered: 02/06/2023) (6) |
| Feb 2, 2023 | 70 | STIPULATION and [Proposed] Claim Construction Order - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 02/02/2023) (6) |
| Feb 1, 2023 | 69 | [SEALED] NOTICE to Take Deposition of Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. on February 27, 2023 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/01/2023) (0) |
| Jan 31, 2023 | 67 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Holdings A/S, Other Affiliate Novo Nordisk Foundation for Novo Nordisk A/S; Corporate Parent Novo Nordisk Commercial Holdings, Inc., Other Affiliate Novo Nordisk A/S, Other Affiliate Novo Nordisk US Holdings Inc. for Novo Nordisk Inc. filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 01/31/2023) (4) |
| Jan 31, 2023 | 68 | NOTICE OF SERVICE of Defendants' Notice of Deposition of Plaintiffs Novo Nordisk, Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(1) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 01/31/2023) (2) |
| Jan 10, 2023 | 65 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 01/10/2023) (11) |
| Jan 10, 2023 | 66 | Letter to The Honorable Colm F. Connolly from Travis Murray regarding claim construction. (Murray, Travis) (Entered: 01/10/2023) (2) |
| Jan 4, 2023 | 64 | REDACTED VERSION of 62 Joint Claim Construction Brief - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 01/04/2023) (30) |
| Dec 29, 2022 | 61 | SO ORDERED, re 59 Stipulation of Dismissal as to Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. Regarding the '154 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 12/29/2022. (kmd) (Entered: 12/29/2022) (4) |
| Dec 29, 2022 | 62 | [SEALED] JOINT CLAIM CONSTRUCTION BRIEF filed by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 12/29/2022) (0) |
| Dec 29, 2022 | 63 | APPENDIX re 62 Joint Claim Construction Brief - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 12/29/2022) (30) |
| Dec 27, 2022 | 59 | STIPULATION and [Proposed] Order of Dismissal as to Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. Regarding the '154 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 12/27/2022) (4) |
| Dec 27, 2022 | 60 | NOTICE OF SERVICE of Defendants' Surreply Claim Construction Brief filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 12/27/2022) (2) |
| Dec 15, 2022 | 58 | NOTICE OF SERVICE of Defendants' First Amended Preliminary Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 12/15/2022) (2) |
| Dec 12, 2022 | 56 | NOTICE OF SERVICE of Novo Nordisk's Reply Claim Construction Brief - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 12/12/2022) (4) |
| Dec 12, 2022 | 57 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' Second Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 73-75) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 12/12/2022) (4) |
| Dec 5, 2022 | 55 | NOTICE OF SERVICE of Defendants' Answering Claim Construction Brief filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) (Entered: 12/05/2022) (2) |
| Nov 11, 2022 | 53 | NOTICE OF SERVICE of Defendants' Second Set of Requests to Plaintiffs for the Production of Documents and Things (No. 73 - 75) filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 11/11/2022) (3) |
| Nov 11, 2022 | 54 | NOTICE OF SERVICE of Novo Nordisk's Opening Claim Construction Brief - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/11/2022) (4) |
| Oct 27, 2022 | 50 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A - '833 Patent, # 2 Exhibit B - '154 Patent, # 3 Exhibit C - '718 Patent, # 4 Exhibit D - '893 Patent)(Murray, Travis) (Entered: 10/27/2022) (Main Document) (29) |
| Oct 27, 2022 | 51 | MOTION for Claim Construction re 50 Claim Construction Chart - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/27/2022) (4) |
| Oct 27, 2022 | 52 | MOTION for Claim Construction [Defendants Motion for Claim Construction] - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 10/27/2022) (2) |
| Oct 27, 2022 | 50 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A - '833 Patent, # 2 Exhibit B - '154 Patent, # 3 Exhibit C - '718 Patent, # 4 Exhibit D - '893 Patent)(Murray, Travis) (Entered: 10/27/2022) (Exhibit A - '833 Patent) (23) |
| Oct 27, 2022 | 50 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A - '833 Patent, # 2 Exhibit B - '154 Patent, # 3 Exhibit C - '718 Patent, # 4 Exhibit D - '893 Patent)(Murray, Travis) (Entered: 10/27/2022) (Exhibit B - '154 Patent) (24) |
| Oct 27, 2022 | 50 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A - '833 Patent, # 2 Exhibit B - '154 Patent, # 3 Exhibit C - '718 Patent, # 4 Exhibit D - '893 Patent)(Murray, Travis) (Entered: 10/27/2022) (Exhibit C - '718 Patent) (7) |
| Oct 27, 2022 | 50 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A - '833 Patent, # 2 Exhibit B - '154 Patent, # 3 Exhibit C - '718 Patent, # 4 Exhibit D - '893 Patent)(Murray, Travis) (Entered: 10/27/2022) (Exhibit D - '893 Patent) (9) |
| Oct 24, 2022 | 49 | NOTICE OF SERVICE of Plaintiffs' Proposed Claim Constructions - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/24/2022) (4) |
| Oct 17, 2022 | 47 | NOTICE OF SERVICE of Defendants' Preliminary Proposed Claim Terms to be Construed filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Hoeschen, Nathan) (Entered: 10/17/2022) (3) |
| Oct 17, 2022 | 48 | NOTICE OF SERVICE of Plaintiffs' Preliminary Identification of Claim Terms and Phrases for Construction - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/17/2022) (4) |
| Oct 10, 2022 | 46 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions; and (2) Novo Nordisk's Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,114,833; 9,457,154; 9,101,718; and 9,265,893 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/10/2022) (4) |
| Aug 31, 2022 | 45 | REDACTED VERSION of 43 Answer to Amended Complaint by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) (Entered: 08/31/2022) (30) |
| Aug 30, 2022 | 44 | NOTICE OF SERVICE of (1) Plaintiffs' First Amended Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Plaintiffs' First Amended Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 08/30/2022) (4) |
| Aug 24, 2022 | 43 | [SEALED] ANSWER to Amended Complaint, re: 34 Amended Complaint by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) (Entered: 08/24/2022) (0) |
| Aug 22, 2022 | 41 | NOTICE OF SERVICE of 1. Defendants' Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-14) 2. Defendants' Objections and Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-72) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) (Entered: 08/22/2022) (2) |
| Aug 22, 2022 | 42 | NOTICE OF SERVICE of (1) Defendants' Preliminary Invalidity Contentions (2) Defendants' Initial Non-Infringement Contentions filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) (Entered: 08/22/2022) (2) |
| Aug 16, 2022 | 40 | NOTICE OF SERVICE of (1) Plaintiffs' Responses and Objections to Defendants' First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-72); and (2) Plaintiffs' Responses and Objections to Defendants' First Set of Interrogatory Requests (Nos. 1-12) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/16/2022) (4) |
| Aug 9, 2022 | 39 | STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the amended complaint to August 24, 2022 - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) (Entered: 08/09/2022) (2) |
| Aug 3, 2022 | 37 | Redacted Document (30) Docket Text: REDACTED VERSION of [32] MOTION for Leave to File First Amended Complaint (Unopposed) by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
| Aug 3, 2022 | 38 | Redacted Document (30) Docket Text: REDACTED VERSION of [34] Amended Complaint by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) |
| Aug 3, 2022 | 38 | Amended Complaint* (1) |
| Aug 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [36] MOTION for Pro Hac Vice Appearance of Attorney Diva R. Hollis, filed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. Ordered by Judge Colm F. Connolly on 8/2/2022. (kmd) |
| Aug 2, 2022 | 36 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Diva R. Hollis - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) |
| Jul 27, 2022 | 33 | Order on Motion for Leave to File (1) Docket Text: ORDER granting [32] Motion for Leave to File First Amended Complaint (Unopposed). Signed by Judge Colm F. Connolly on 7/27/2022. (kmd) |
| Jul 27, 2022 | 35 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,114,833 ;9,457,154 ;9,101,718 ;9,265,893 . (Egan, Brian) |
| Jul 13, 2022 | 31 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-72); and (2) Plaintiffs' First Set of Interrogatories (Nos. 1-14) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
| Jul 12, 2022 | 30 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1. Defendants' First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-73) 2. Defendants' First Set of Interrogatory Requests to Plaintiffs (Nos. 1-12) filed by Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) |
| Jun 24, 2022 | 29 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Preliminary Disclosure of Asserted Patents and Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
| Jun 15, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [28] Stipulation Regarding the Discovery of Electronically Stored Information, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 6/15/2022. (kmd) |
| Jun 14, 2022 | 27 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants' Rule 26(a) Initial Disclosure Statement (2) Defendants Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.'s Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jun 14, 2022 | 28 | Stipulation (15) Docket Text: STIPULATION Regarding the Discovery of Electronically Stored Information by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Jun 13, 2022 | 26 | SO ORDERED (2) Docket Text: SO ORDERED, re [24] STIPULATION TO EXTEND TIME to submit a proposed order for the discovery of electronically-stored information ("ESI Order") to June 14, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/13/2022. (kmd) |
| Jun 10, 2022 | 24 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to submit a proposed order for the discovery of electronically-stored information ("ESI Order") to June 14, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Jun 10, 2022 | 25 | Notice Requesting Removal of Co-Counsel (3) Docket Text: NOTICE requesting Clerk to remove Kara N. Czekai as co-counsel. Reason for request: No longer with firm. (Egan, Brian) |
| Jun 3, 2022 | 23 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure; and (2) Plaintiffs' Disclosures Under Paragraph 3 of the District of Delaware Default Standard filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) |
| May 20, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [21] MOTION for Pro Hac Vice Appearance of Attorney Erica R. Sutter and Olivia Wheeling, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 5/20/2022. (kmd) |
| May 20, 2022 | 21 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Erica R. Sutter and Olivia Wheeling - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| May 20, 2022 | 22 | Scheduling Order (29) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 3/24/2023. Amended Pleadings due by 3/24/2023. Fact Discovery completed by 3/24/2023. Expert Discovery due by 7/28/2023. Joint Claim Construction Brief due by 12/29/2022. A Markman Hearing is set for 1/26/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 9/28/2023. A Final Pretrial Conference is set for 10/19/2023 at 02:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 11/13/2023 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 5/20/2022. (nmf) |
| May 17, 2022 | 20 | Proposed Order (29) Docket Text: PROPOSED ORDER -- Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| May 12, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Colm F. Connolly - Scheduling Conference held on 5/12/2022. (Court Reporter Bonnie Archer.) Counsel to resubmit the proposed scheduling order with a revised order reflecting the Court's rulings, no later than May 17, 2022. (nmf) |
| May 10, 2022 | 19 | Proposed Order (30) Docket Text: PROPOSED ORDER -- Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Apr 27, 2022 | N/A | Set Deadlines/Hearings (0) Docket Text: Reset Hearings: The Scheduling Conference is rescheduled per request of counsel for 5/12/2022 at 02:00 PM Telephonically before Judge Colm F. Connolly. (nmf) |
| Apr 26, 2022 | N/A | Remark (0) Docket Text: The 4/29/2022 Scheduling Conference is postponed per request of counsel. It will be rescheduled to a new date soon. (nmf) |
| Apr 21, 2022 | 18 | Protective Order (30) Docket Text: STIPULATED PROTECTIVE ORDER. Signed by Judge Colm F. Connolly on 4/21/2022. (kmd) |
| Apr 20, 2022 | 17 | Proposed Order (30) Docket Text: PROPOSED ORDER -- Protective Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Mar 30, 2022 | 16 | Order Setting Scheduling Conference (1) Docket Text: Order Setting Telephonic Scheduling Conference: A Scheduling Conference is set for 4/29/2022 at 08:30 AM Telephonically before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 3/30/2022. (nmf) |
| Mar 17, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [15] MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, and Kara N. Czekai, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 3/17/2022. (kmd) |
| Mar 17, 2022 | 15 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, and Kara N. Czekai - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Mar 10, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Mark C. McLennan, Thomas F. Fleming, Andrew B Walter, and Jeanna M. Wacker for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Mar 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [14] MOTION for Pro Hac Vice Appearance of Attorney Thomas F. Fleming, Mark C. McLennan, Andrew B. Walter and Jeanna M. Wacker, filed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. Ordered by Judge Colm F. Connolly on 3/9/2022. (kmd) |
| Mar 9, 2022 | 14 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Thomas F. Fleming, Mark C. McLennan, Andrew B. Walter and Jeanna M. Wacker - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) |
| Mar 4, 2022 | 13 | Letter (1) Docket Text: Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding coordinated discovery and Markman - re (13 in 1:21-cv-01783-CFC, 13 in 1:21-cv-01783-CFC, 10 in 1:21-cv-01782-CFC, 10 in 1:21-cv-01782-CFC) Order,, Set Deadlines,. (Egan, Brian) |
| Feb 11, 2022 | 11 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, and Affirmative Defenses by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc..(Keller, Karen) |
| Feb 11, 2022 | 12 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Keller, Karen) |
| Feb 4, 2022 | 10 | Order (2) Docket Text: ORDER: IT IS ORDERED that, on or before March 4, 2022, counsel for plaintiffs shall inform the court as to whether the need for coordinated discovery and/or Markman proceedings is anticipated as to the above cases and, if so, when a joint scheduling conference might most efficiently be conducted.ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 3/4/2022.) Signed by Judge Colm F. Connolly on 2/4/2022. Associated Cases: 1:21-cv-01782-CFC, 1:21-cv-01783-CFC(nmf) |
| Jan 4, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the complaint to February 11, 2022 filed by Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Set/Reset Answer Deadlines: Teva Pharmaceuticals USA, Inc. answer due 2/11/2022; Teva Pharmaceuticals, Inc. answer due 2/11/2022. Signed by Judge Colm F. Connolly on 1/4/2022. (nmf) |
| Dec 29, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:21-cv-01782-CFC, 1:21-cv-01783-CFC (rjb) |
| Dec 29, 2021 | 9 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the complaint to February 11, 2022 - filed by Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) |
| Dec 22, 2021 | 6 | Main Document (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceuticals USA, Inc. on 12/22/2021; and Teva Pharmaceuticals, Inc. on 12/22/2021. (Attachments: # (1) Summons Issued)(mal) |
| Dec 22, 2021 | 6 | Summons Issued (2) |
| Dec 22, 2021 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novo Nordisk Inc., Novo Nordisk A/S. Teva Pharmaceuticals, Inc. served on 12/22/2021, answer due 1/12/2022. (Blumenfeld, Jack) |
| Dec 22, 2021 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novo Nordisk Inc., Novo Nordisk A/S. Teva Pharmaceuticals USA, Inc. served on 12/22/2021, answer due 1/12/2022. (Blumenfeld, Jack) |
| Dec 21, 2021 | 1 | Main Document (25) Docket Text: COMPLAINT filed against Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3768371.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # (1) Exhibit A-Q, # (2) Civil Cover Sheet)(mal) |
| Dec 21, 2021 | 1 | Exhibit A-Q (296) |
| Dec 21, 2021 | 1 | Civil Cover Sheet (1) |
| Dec 21, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Dec 21, 2021 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/12/2021. Date of Expiration of Patent: see attached.Thirty Month Stay Deadline: 5/12/2024. (mal) |
| Dec 21, 2021 | 4 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) see attached. (mal) |
| Dec 21, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo A/S for Novo Nordisk A/S; Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc.; and Novo Nordisk US Holdings Inc. is a privately held corporation wholly owned by Novo Nordisk A/S. - filed by Novo Nordisk A/S and Novo Nordisk Inc.. (mal) |
| Dec 21, 2021 | 1 | Complaint* (1) |
